RECURRENT OVARIAN CARCINOMA

This study looks at three different drug combinations for women with ovarian, fallopian tube, or primary peritoneal cancer that has returned and is no longer responding to platinum-based chemotherapy. The trial compares a standard chemotherapy drug (pegylated liposomal doxorubici…

This study tests a new treatment for ovarian cancer that has come back after standard therapy. It uses stem cells loaded with a modified measles virus to deliver cancer-killing effects directly into the abdomen. The trial involves 34 participants and aims to find the safest dose …

This study tested whether the targeted drugs olaparib (alone or with cediranib) work better than standard platinum-based chemo for women with ovarian, fallopian tube, or peritoneal cancer that came back after initial treatment. About 579 women with platinum-sensitive cancer took …

This early-phase study tests a combination of two oral and intravenous drugs (niraparib and copanlisib) in about 31 people whose endometrial, ovarian, or related cancers have returned. The main goal is to find the safest dose and understand side effects. Participants must have ce…

This study tests whether combining an immunotherapy drug (pembrolizumab) with chemotherapy (carboplatin) can delay cancer progression in people with ovarian, fallopian tube, or primary peritoneal cancer that has returned. Participants have a rising CA-125 blood marker but no visi…

This early-stage trial tests a new treatment for ovarian, fallopian tube, or peritoneal cancer that has returned or not responded to standard therapy. Patients receive their own immune cells (T cells) that have been genetically modified to recognize and attack cancer cells, along…

This study tests whether adding the experimental drug AZD1775 to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 participants will receive either the combination…

This early-phase trial tests whether adding an experimental drug (berzosertib) to standard chemotherapy (carboplatin and gemcitabine) is safe and effective for people with ovarian, peritoneal, or fallopian tube cancer that has returned and spread. The study involves 35 participan…

This study tests two different chemotherapy combinations (carboplatin+paclitaxel vs oxaliplatin+capecitabine), with or without the targeted drug bevacizumab, as first treatment for mucinous ovarian or fallopian tube cancer. About 50 patients with newly diagnosed or recurrent dise…

This phase 2 trial tests a personalized cell therapy called LN-145 for people with certain advanced cancers (like ovarian, breast, thyroid, or bone cancers) that have not responded to treatment or have returned. The therapy uses a patient's own immune cells, taken from their tumo…

This study tests a drug called tazemetostat in 62 people whose ovarian or endometrial cancer has returned after previous treatment. The drug works by blocking a protein that helps cancer cells grow. The main goal is to see if the drug can shrink tumors or stop them from growing f…

This early-phase study tests the safety and effectiveness of giving heated chemotherapy directly into the abdomen during surgery for advanced or recurrent ovarian, fallopian tube, uterine, or peritoneal cancer. About 40 participants will receive this treatment, with some also get…

This study tests two drug combinations (olaparib plus either AZD2014 or AZD5363) in people with recurrent endometrial, triple-negative breast, ovarian, or related cancers. The goal is to find the safest dose and see if the drugs can slow or stop tumor growth. About 159 adults who…

This study tests a drug called adavosertib, given alone or with another drug (olaparib), in women with ovarian, fallopian tube, or peritoneal cancer that has returned and stopped responding to PARP inhibitors. About 96 participants will receive one of the two treatments to see if…

This study looked at whether combining two targeted drugs (cediranib and olaparib) works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that came back or grew during platinum-based chemo. About 582 women took pa…

This study tests a new three-drug combination (lenvatinib, pembrolizumab, and paclitaxel) in women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned after prior treatment. The goal is to see if the combination shrinks tumors and to check for si…

This study tests a combination of two drugs, veliparib and topotecan, in people with solid tumors or ovarian cancer that has returned after initial treatment. The goal is to find the safest dose and see if the combo can shrink tumors. About 88 adults are taking part in this early…

This study tests the drug pembrolizumab in 21 adults with advanced solid tumors that have specific gene mutations (BRCA1, BRCA2, POLE, or POLD1). The goal is to see if the drug can shrink or control the cancer. Pembrolizumab is a type of immunotherapy that helps the immune system…

This study tests whether adding an experimental drug called M6620 to standard chemotherapy (gemcitabine) works better than gemcitabine alone for women with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 70 par…

This early-phase trial tests a new drug (MLN0128) combined with bevacizumab in people with recurrent glioblastoma (a brain cancer) or other advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and understand side ef…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The main goal is to find the safest dose and check for side effects. About 54 participants …

This study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with ovarian, peritoneal, or fallopian tube cancer that has come back live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus beva…

This study tests a program called HOPE, designed to help women with recurrent ovarian cancer feel less hopeless and helpless. About 60 participants will either receive the HOPE workshops or standard care. The goal is to see if the program improves emotional well-being and quality…

This study looks at whether doctors can consistently measure the chemotherapy drug paclitaxel in the blood of cancer patients. The goal is to see if this could help adjust doses to kill cancer while reducing nerve damage, a common side effect. About 22 adults with various solid t…

This study tests whether analyzing the genes of a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to standard therapy are enrolled. The goal is to see if targe…